Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry(Pennsylvania Hospital), Howard Yeh(Hospital de Santa Maria), Saroj Vadhan‐Raj(The University of Texas MD Anderson Cancer Center), Jana Prausová(University Hospital in Motol), Roger von Moos(Kantonsspital Graubünden), Roger Dansey(Memorial Sloan Kettering Cancer Center), Vera Hirsh(Taipei Veterans General Hospital), Qi Jiang(National Cancer Centre Japan), H.P. Sleeboom(Unknown), Andrew Spencer(The Alfred Hospital), François Goldwasser(Hôpital Cochin), Wolfgang Willenbacher(Universität Innsbruck), Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Jianming Wang(China-Japan Friendship Hospital), Vânia Hungria(Faculdade de Ciências Médicas da Santa Casa de São Paulo), Susie Jun(Ellis Hospital), Luís Costa(University of Lisbon), Penella J. Woll(University of Sheffield)
Cited by 1,259
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k